Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 70.03% is in line with its 5-year average of 71.32%, near the low end of its 5-year range (62.18%–95.76%).
0.70% below its 12-month average of 70.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 74.48%.
GROSS MARGIN
70.03%
GROSS MARGIN AVG TTM
70.52%
GROSS MARGIN AVG 3Y
68.57%
GROSS MARGIN AVG 5Y
71.32%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.70%
CURRENT VS 3Y AVG
+2.13%
CURRENT VS 5Y AVG
-1.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+69.24%
vs the sector median at left
10x Genomics, Inc.
Market Cap
$10.20B
Gross Margin
70.03%
TTM Avg
70.52%
3Y Avg
68.57%
5Y Avg
71.32%
Market Cap
$10.21B
Gross Margin
13.07%
TTM Avg
12.36%
3Y Avg
12.43%
5Y Avg
12.55%
Market Cap
$10.14B
Gross Margin
66.48%
TTM Avg
69.16%
3Y Avg
69.73%
5Y Avg
70.75%
Market Cap
$10.30B
Gross Margin
68.55%
TTM Avg
63.16%
3Y Avg
66.39%
5Y Avg
68.84%
Market Cap
$10.03B
Gross Margin
14.14%
TTM Avg
15.74%
3Y Avg
16.11%
5Y Avg
16.54%
Market Cap
$10.39B
Gross Margin
51.97%
TTM Avg
46.66%
3Y Avg
42.83%
5Y Avg
40.38%
Market Cap
$9.93B
Gross Margin
51.90%
TTM Avg
52.87%
3Y Avg
53.77%
5Y Avg
54.60%
Market Cap
$9.89B
Gross Margin
51.05%
TTM Avg
45.19%
3Y Avg
47.81%
5Y Avg
50.44%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 10x Genomics, Inc. (TXG) | $10.20B | 70.03% | 70.52% | 68.57% | 71.32% |
| Molina Healthcare, Inc. (MOH)vs › | $10.21B | 13.07% | 12.36% | 12.43% | 12.55% |
| Align Technology, Inc. (ALGN)vs › | $10.14B | 66.48% | 69.16% | 69.73% | 70.75% |
| ImmunityBio, Inc. (IBRX)vs › | $10.12B | 94.63% | 99.67% | 99.84% | 99.89% |
| Globus Medical, Inc. (GMED)vs › | $10.30B | 68.55% | 63.16% | 66.39% | 68.84% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 14.14% | 15.74% | 16.11% | 16.54% |
| Twist Bioscience Corporation (TWST)vs › | $10.39B | 51.97% | 46.66% | 42.83% | 40.38% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 51.90% | 52.87% | 53.77% | 54.60% |
| Repligen Corporation (RGEN)vs › | $9.89B | 51.05% | 45.19% | 47.81% | 50.44% |
| Universal Health Services, Inc. (UHS)vs › | $10.70B | 90.69% | 90.21% | 89.67% | 89.38% |
Gross Margin
70.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.48% |
| 2026-03-31 | 70.39% |
| 2025-12-31 | 68.09% |
| 2025-09-30 | 67.32% |
| 2025-06-30 | 72.34% |
| 2025-03-31 | 68.08% |
| 2024-12-31 | 67.24% |
| 2024-09-30 | 70.16% |
| 2024-06-30 | 68.07% |
| 2024-03-31 | 65.89% |
| 2023-12-31 | 62.93% |
| 2023-09-30 | 62.18% |
| 2023-06-30 | 67.85% |
| 2023-03-31 | 73.27% |
| 2022-12-31 | 76.43% |
| 2022-09-30 | 76.82% |
| 2022-06-30 | 75.83% |
| 2022-03-31 | 77.75% |
| 2021-12-31 | 80.77% |
| 2021-09-30 | 80.43% |
| 2021-06-30 | 95.76% |
| 2021-03-31 | 83.88% |
| 2020-12-31 | 83.16% |
| 2020-09-30 | 79.93% |
| 2020-06-30 | 76.57% |
| 2020-03-31 | 78.99% |
| 2019-12-31 | 77.98% |
| 2019-09-30 | 74.71% |
| 2019-06-30 | 73.12% |
| 2019-03-31 | 73.94% |
| 2018-12-31 | 70.53% |
| 2018-09-30 | 85.68% |
| 2018-06-30 | 85.67% |
| 2018-03-31 | 85.60% |
